Innovent Biologics financials at a glance

+ Portfolio

The revenue of Innovent Biologics is reported as 5.89795 billion Dollars in the fiscal year 2023. The earnings were -0.78 Dollars per share in 2023, which was 7.14 lower than 2021. And about -0.76275 billion Dollars are reported as free cash flow in the financials of Innovent Biologics 2023. No dividends were paid to the shareholders of the Innovent Biologics stock SEHK:1801 in the financial year 2023.

HK$4.56B

Revenue

HK$-1.65

Earnings Per Share

69.67%

Gross Margin %

HK$-2,815.70M

Free Cash Flow

Revenue

4,556.38

Earnings Per Share

-1.65

Gross Margin %

69.67

Free Cash Flow

-2,815.70

Financials

Year	Year	TTM	2022	2021	2020	2019	2018	2017
Rev.	Revenue	N/A	HK$4.56B	HK$4.27B	HK$3.84B	HK$1.05B	HK$9.48M	HK$18.54M
GM %	Gross Margin %	71.00%	69.67%	71.32%	79.92%	88.08%	100.00%	0.00%
OM	Operating Margin	-47.68%	-68.54%	-63.31%	-14.50%	-,173.71%	0.00%	0.00%
EPS	Earnings Per Share	HK$-0.90	HK$-1.65	HK$-1.54	HK$-0.44	HK$-1.33	HK$-1.25	HK$-5.52
Div.	Dividends	N/A	HK$0.00	HK$0.00	HK$0.00	HK$0.00	HK$0.00	HK$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%
Sha.	Shares	N/AM	1,534.41M	1,462.11M	1,402.78M	1,262.56M	1,153.6M	119.89M
OCF	Operating Cash Flow	N/A	HK$-1,918.80M	HK$-2,024.84M	HK$-,307.69M	HK$-1,664.47M	HK$-1,016.02M	HK$0.00M
FCF	Free Cash Flow	N/A	HK$-2,815.70M	HK$-3,090.48M	HK$-,796.71M	HK$-2,030.35M	HK$-1,328.76M	HK$0.00M
FCFS	Free Cash Flow Per Share	HK$-2.13	HK$-2.20	HK$-2.66	HK$-0.61	HK$-1.72	HK$-3.96	HK$0.00

Innovent Biologics financials at a glance

Financials

Discover